5315992025-01-012025-03-315315992025-03-315315992024-03-315315992024-04-012025-03-315315992025-01-012025-03-31in-capmkt:OtherExpenses1Member5315992024-04-012025-03-31in-capmkt:OtherExpenses1Member5315992025-01-012025-03-31ItemsThatWillNotBeReclassifiedToProfitAndLoss15315992024-04-012025-03-31ItemsThatWillNotBeReclassifiedToProfitAndLoss15315992025-01-012025-03-31ItemsThatWillBeReclassifiedToProfitAndLoss15315992024-04-012025-03-31ItemsThatWillBeReclassifiedToProfitAndLoss1iso4217:INRiso4217:INRxbrli:shares531599FDCNOTLISTEDINE258B01022FDC LIMITEDMain BoardEquity2024-04-012025-03-312025-05-282025-05-22INRLakhsQuarterlyFourth quarterSingle segmentPharmaceutical2025-05-2812:30:002025-05-2815:40:00trueCash Flow IndirectNot applicable2025-01-012025-03-31AuditedConsolidated491889300016078800050796810001566375000326227000-279180000121605800011922000155619000154957600045465970005330840000533084000156544000-1017300014637100003867130000000386713000-3845000034826300016281000012.382.38002.382.381. The above unaudited consolidated financial results which are published in accordance with Regulation 33 of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015 (‘Listing Regulations’) for the quarter and financial year ended March 31, 2025 have been reviewed by the Audit Committee and approved by the Board of Directors of the Parent Company at their meeting held on May 28, 2025. The Statutory Auditors have expressed an unmodified audit opinion. The audit report has been filed with the stock exchange and is available on the Company’s website. <BR> <BR> 2. The Parent Company recognized a fair value loss ofRs. 197.01 lakhs under other expenses in the quarter ended March 31, 2025 in accordance with Ind AS 109 (Financial Instruments). However, for the financial year ended March 31, 2025, a net fair value gain of Rs 2,430.09 lakhs was recorded under Other Income. Due to this treatment, the quarterly numbers may not be directly additive to the year-to-date (YTD) numbers, as fair value changes are recognized based on market conditions prevailing at different reporting dates. <BR> <BR> 3. During the current financial year, the Parent Company has paid an Interim Dividend of Rs. 5/- per equity share of face value Rs.1/- each for the Financial Year 2024-25, as approved by the Board of Directors of the Parent Company at their meeting held on November 6, 2024. <BR> <BR> 4. During the previous year, the Parent Company had completed the buyback of 31,00,000 equity shares having face value of Rs. 1/- each at a price of Rs. 500/- per share on September 13, 2023. The number of equity shares post buyback stands reduced to 16,28,10,084 shares having face value of Rs. 1/- each. Accordingly, the paid-up share capital also stands reduced to Rs. 16,28,10,084. <BR> <BR> 5. The Group has only one segment of activity namely “Pharmaceuticals”. <BR> <BR> 6. The above results are also available on the website of the Parent Company i.e. www.fdcindia.com and on the website of the Stock Exchanges i.e. www.nseindia.com and www.bseindia.com2024-04-012025-03-31AuditedConsolidated210812040009066080002198781200058124410001274402000275942000482367200045096000537322000564676100018415636000357217600003572176000859440000448550009042950000266788100000002667881000-14717000265316400016281000012264799500016.3916.390016.3916.39Other Expenses1549576000Other Expenses564676100084804230001360942000035036000749700054316860008134000337510005473571000893400000162508690003750321000484651800010884740005147240001299500014403000493980006526512000576036000108528690003428400027138022000162810000226479950002281080500022810805000109700000001097000360672000229006000012006900071084400001238360001927699000205153500099991500030514500002462410002402780007840400036163730004327217000271380220004509600017013700078156000014296800000157420000410873000000537322000061475000000-2216000000-2430090000-103453000-2387000-5257000011054470004677623000-360000-4738430001028008000031757360000000000057875000967246000000000000003813804000537318000000003600047356700000-199514400000000000032100010181200081133700000-7762000-9212320002593600001163000260523000254201000514724000Amount of items that will not be reclassified to profit and loss-30457000-30457000Amount of items that will not be reclassified to profit and loss-26670000-26670000-4829000-4350000Amount of items that will be reclassified to profit and loss-12822000-12822000Amount of items that will be reclassified to profit and loss7603000760300000-38450000-14717000